A detailed history of Price T Rowe Associates Inc transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,014,259 shares of IGMS stock, worth $35.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,014,259
Previous 4,075,091 1.49%
Holding current value
$35.7 Million
Previous $28 Million 137.16%
% of portfolio
0.01%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.28 - $17.68 $382,024 - $1.08 Million
-60,832 Reduced 1.49%
4,014,259 $66.4 Million
Q2 2024

Aug 14, 2024

BUY
$6.51 - $11.47 $1.22 Million - $2.15 Million
187,068 Added 4.81%
4,075,091 $28 Million
Q1 2024

May 15, 2024

BUY
$8.68 - $17.36 $5.45 Million - $10.9 Million
628,001 Added 19.26%
3,888,023 $37.5 Million
Q4 2023

Feb 14, 2024

BUY
$3.94 - $8.79 $68,189 - $152,128
17,307 Added 0.53%
3,260,022 $27.1 Million
Q3 2023

Nov 14, 2023

BUY
$6.66 - $10.64 $78,887 - $126,030
11,845 Added 0.37%
3,242,715 $27.1 Million
Q2 2023

Aug 14, 2023

BUY
$8.86 - $14.0 $9.83 Million - $15.5 Million
1,109,995 Added 52.34%
3,230,870 $29.8 Million
Q1 2023

May 15, 2023

SELL
$13.74 - $25.76 $1.18 Million - $2.2 Million
-85,532 Reduced 3.88%
2,120,875 $29.1 Million
Q4 2022

Feb 14, 2023

SELL
$15.45 - $26.02 $175,496 - $295,561
-11,359 Reduced 0.51%
2,206,407 $37.5 Million
Q3 2022

Nov 14, 2022

SELL
$15.42 - $27.01 $6.25 Million - $10.9 Million
-405,107 Reduced 15.45%
2,217,766 $50.4 Million
Q2 2022

Aug 15, 2022

BUY
$13.27 - $25.5 $5 Million - $9.61 Million
376,832 Added 16.78%
2,622,873 $47.3 Million
Q1 2022

May 16, 2022

SELL
$13.42 - $29.73 $1.68 Million - $3.72 Million
-125,234 Reduced 5.28%
2,246,041 $60 Million
Q4 2021

Feb 14, 2022

BUY
$27.59 - $66.39 $381,045 - $916,912
13,811 Added 0.59%
2,371,275 $69.5 Million
Q3 2021

Nov 15, 2021

BUY
$65.76 - $90.65 $24.4 Million - $33.7 Million
371,393 Added 18.7%
2,357,464 $155 Million
Q2 2021

Aug 16, 2021

BUY
$57.98 - $96.6 $11 Million - $18.3 Million
189,760 Added 10.56%
1,986,071 $165 Million
Q1 2021

May 17, 2021

BUY
$71.56 - $121.23 $33.5 Million - $56.7 Million
467,527 Added 35.18%
1,796,311 $138 Million
Q4 2020

Feb 16, 2021

BUY
$47.41 - $115.03 $63 Million - $153 Million
1,328,784 New
1,328,784 $117 Million

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $258M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.